Pulmonx Debt/Equity Ratio 2019-2024 | LUNG

Pulmonx debt/equity ratio from 2019 to 2024. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Pulmonx Debt/Equity Ratio 2019-2024 | LUNG

Pulmonx debt/equity ratio from 2019 to 2024. Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
GE HealthCare Technologies (GEHC)$40.4B
Tempus AI (TEM)$7.9B
Inspire Medical Systems (INSP)$6.2B
Axonics (AXNX)$3.5B
Hims & Hers Health (HIMS)$3.5B
10x Genomics (TXG)$2.7B
Enovis (ENOV)$2.4B
Azenta (AZTA)$2.4B
Privia Health (PRVA)$2.3B
IRhythm Technologies (IRTC)$2.2B
Omnicell (OMCL)$2B
Clover Health Investments (CLOV)$1.5B
Schrodinger (SDGR)$1.4B
Phreesia (PHR)$1.4B
Standard BioTools (LAB)$753M
Fulgent Genetics (FLGT)$694M
Definitive Healthcare (DH)$538M
Health Catalyst (HCAT)$529M
Butterfly Network (BFLY)$406M
Talkspace (TALK)$343M
SOPHiA GENETICS SA (SOPH)$286M
TruBridge (TBRG)$183M
P3 Health Partners (PIII)$165M
American Well (AMWL)$147M
Augmedix (AUGX)$115M
EUDA Health Holdings (EUDA)$90M
Future Health ESG (FHLT)$65M
SHL Telemedicine (SHLT)$55M
HeartBeam (BEAT)$53M
111 (YI)$51M